Your browser doesn't support javascript.
loading
Pre-existing Symptoms and Healthcare Utilization Prior to Diagnosis of Neuroendocrine Tumors: A SEER-Medicare Database Study.
Shen, C; Dasari, A; Xu, Y; Zhou, S; Gu, D; Chu, Y; Halperin, D M; Shih, Y T; Yao, J C.
Affiliation
  • Shen C; Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Dasari A; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Xu Y; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Zhou S; Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Gu D; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Chu Y; Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Halperin DM; Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Shih YT; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Yao JC; Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, USA.
Sci Rep ; 8(1): 16863, 2018 11 15.
Article in En | MEDLINE | ID: mdl-30442902
ABSTRACT
The incidence and prevalence of neuroendocrine tumors (NETs) are continually increasing. While it is known that NET symptoms often predate diagnosis, their prevalence and impact on resource utilization and costs are largely unknown. We identified 9,319 elderly patients diagnosed with NETs between 1/2003 and 12/2011 from the Surveillance, Epidemiology and End Results (SEER)-Medicare. We examined the patients' conditions potentially associated with NET, resource utilization and costs during the year before diagnosis. We found that NET patients were more likely to have diagnoses of hypertension (63.8% vs. 53.3%), abdominal pain (22.2% vs. 7.6%), heart failure (11.7% vs. 8.0%), diarrhea (5.8% vs. 1.8%), peripheral edema (5.4% vs. 3.8%) and irritable bowel syndrome (1.2% vs. 0.5%) compared to the non-cancer control group. They also had much higher resource utilization including number of outpatient visits (mean 22.1 vs. 17.2), percentage with ER visits (20.9% vs. 11.6%), and hospitalizations (28.4% vs. 17.0%). Similarly, NET patients incurred significantly higher total (mean $14602 vs. $9464), outpatient (mean $5987 vs. $4253), and inpatient costs (mean $8615 vs. $5211). This first population-based study on the pre-diagnosis symptoms and healthcare utilization found that NET patients were more likely to have certain conditions and incur higher resource utilizations and costs.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Patient Acceptance of Health Care / Neuroendocrine Tumors / SEER Program Type of study: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Aspects: Implementation_research Limits: Aged / Aged80 / Humans Language: En Journal: Sci Rep Year: 2018 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Patient Acceptance of Health Care / Neuroendocrine Tumors / SEER Program Type of study: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Aspects: Implementation_research Limits: Aged / Aged80 / Humans Language: En Journal: Sci Rep Year: 2018 Document type: Article Affiliation country: